Development of a cytomegalovirus vaccine: lessons from recent clinical trials. - Wikidata - wikimedia - TriplyDB

Development of a cytomegalovirus vaccine: lessons from recent clinical trials.

Development of a cytomegalovirus vaccine: lessons from recent clinical trials.

http://www.wikidata.org/entity/Q34451960

about

The genome of canarypox virus Human cytomegalovirus: detection of congenital and perinatal infection in Argentina Vaccines: the Fourth Century Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge A spread-deficient cytomegalovirus for assessment of first-target cells in vaccination.The glycoprotein B disintegrin-like domain binds beta 1 integrin to mediate cytomegalovirus entry.Recent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases.Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties.Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers.New and emerging vaccination strategies for prevention and treatment of dermatological diseases.Vaccine strategies against human cytomegalovirus infection.Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity.Production of Cytomegalovirus Dense Bodies by Scalable Bioprocess Methods Maintains Immunogenicity and Improves Neutralizing Antibody Titers.A CMV vaccine: TREATing despite the TRICKs.Cytomegalovirus and varicella-zoster virus vaccines in hematopoietic stem cell transplantation.Defining the risks for cytomegalovirus infection and disease after solid organ transplantation.Immune-based therapies for cytomegalovirus infection.Innate immune recognition of poxviral vaccine vectors.Guinea pig cytomegalovirus GP84 is a functional homolog of the human cytomegalovirus (HCMV) UL84 gene that can complement for the loss of UL84 in a chimeric HCMV.Glycoprotein B genotyping in congenital/perinatal Cytomegalovirus infection in symptomatic infants.Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.

P2860

Q24630284-0A62BCF2-B21B-4465-A862-DB5F1B9AA9A1 Q24801969-8204247A-19A0-43DE-87DC-A3C3A64FBA46 Q27490454-8E1E5E74-E36F-45F6-B39A-E5E6FEE77078 Q33551402-892AE0F3-6BDF-4AB2-ADD9-BE5C8A13EF6C Q33964131-49AD7AA1-4BF4-4753-BA32-D17AB1CF8402 Q34120904-FF910358-F575-4EAD-970A-41CCEB5ABD96 Q34349745-BA432948-7D93-4641-B2EC-720A07CB75CC Q34360228-7E26F800-76A2-4AE3-96DF-EF48CFE3239D Q34975513-E373DCF1-108B-4F63-AEA9-95562FB89067 Q35843635-69C4A5D4-88E9-43BC-ACF5-BF09C5887FA6 Q36839736-A3C2F7FD-1AD0-4AAF-ABAC-2242EC1B55D2 Q37243886-EA985556-2BAE-44A1-A392-387A82C555D5 Q37409233-05D605C0-F3BC-4159-A627-3D0D825E162A Q37523988-344EDA4B-D33C-4D9B-92B3-09CBD102E9B5 Q37559627-A8EECB05-A270-4306-8D26-A6DD0F65158C Q37680941-566EC85D-23AF-49A2-A99F-38CF6A2636C4 Q37773240-D50AC11E-AC69-439A-9261-F82FA5771676 Q37944321-5F177B16-9F2C-4DC0-9C23-B570E22C9BD6 Q39629189-6C87F78D-BC0D-4BA1-8B65-9ADC841842B5 Q46121992-2F73D38E-9297-419A-B07A-C6F9AF81F7BD Q48331811-E575D497-95F6-4D67-B326-1522CE0CDEBF

P2860

Development of a cytomegalovirus vaccine: lessons from recent clinical trials.

http://www.wikidata.org/entity/Q34451960

description

2001 nî lūn-bûn

@nan

2001 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Development of a cytomegalovirus vaccine: lessons from recent clinical trials.

@ast

Development of a cytomegalovirus vaccine: lessons from recent clinical trials.

@en

Development of a cytomegalovirus vaccine: lessons from recent clinical trials.

@nl

type

label

Development of a cytomegalovirus vaccine: lessons from recent clinical trials.

@ast

Development of a cytomegalovirus vaccine: lessons from recent clinical trials.

@en

Development of a cytomegalovirus vaccine: lessons from recent clinical trials.

@nl

prefLabel

Development of a cytomegalovirus vaccine: lessons from recent clinical trials.

@ast

Development of a cytomegalovirus vaccine: lessons from recent clinical trials.

@en

Development of a cytomegalovirus vaccine: lessons from recent clinical trials.

@nl

P1433

Q34451960-C6EFA8CF-207E-4061-9E40-65613487B69D

P1476

Q34451960-EDC6081F-BEB5-4A55-BE1F-E448A520F106

P2093

Q34451960-7CA0F39E-D5D5-4A92-AB20-514AB1CFC253

P2860

Q34451960-015DB358-AD4E-46E6-B61D-A19844813A22

Q34451960-0B43D0AB-9394-47F9-95B2-AFB843CE49A6

Q34451960-0B59E9B7-6615-4D85-974B-D28D1B5A46AF

Q34451960-0D761A02-A4FD-4924-8C21-9D7194895A52

Q34451960-15F86023-161A-4613-A767-6CCE6AC89B68

Q34451960-1B61E54F-422A-464B-B7D4-D044E4DE7D7D

Q34451960-1C3F6808-E863-4815-8745-5755679C50B9

Q34451960-2AE24A8B-613C-46DD-8B56-2402B7F171FF

Q34451960-2BE7439B-F1A7-456B-9356-0AD2BF88FFEB

Q34451960-51235FE7-70E8-41FC-ACC3-6FC98B6F716B

P304

Q34451960-9585F6D5-4383-467B-976A-8B85DAE62CE7

P31

Q34451960-F9CB0F4D-A040-4F93-A597-40E0B27EB2EC

P356

Q34451960-FBECFB9A-1493-451B-8CFF-7DBBDCC0935F

P407

Q34451960-1D945829-37C7-4082-8B45-EF749903740A

P433

Q34451960-D57E9FBA-9E4A-4376-BB01-07F2E7D0CD34

P478

Q34451960-F82C5F67-429E-4CCD-A0B6-186B0471D66E

P50

Q34451960-E35C08F3-FF9A-4CD4-B27B-54CEEBFB2FA9

P577

Q34451960-FA0DE29F-508F-4D57-A556-6A642E0B8DD8

P698

Q34451960-F0E46A08-504C-4715-B23F-2F1716DF6A0C

P921

Q34451960-8C2FCFAC-F420-471D-90CF-49953BC12BD5

P356

14712598.1.3.401

P1433

Expert Opinion on Biological Therapy

P1476

Development of a cytomegalovirus vaccine: lessons from recent clinical trials.

@en

P2093

Plotkin S

http://www.w3.org/2001/XMLSchema#string

P2860

Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system

Vaccination against cytomegalovirus, the changeling demon.

DNA and RNA-based vaccines: principles, progress and prospects.

The immunogenicity of human and murine cytomegaloviruses.

Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus.

Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus.

Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine.

A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects.

Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response.

Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes.

P304

401-412

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.1.3.401

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

P577

2001-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11727514

http://www.w3.org/2001/XMLSchema#string

P921

Cytomegalovirus